These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 22444679)

  • 41. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
    Mendel DB; Laird AD; Xin X; Louie SG; Christensen JG; Li G; Schreck RE; Abrams TJ; Ngai TJ; Lee LB; Murray LJ; Carver J; Chan E; Moss KG; Haznedar JO; Sukbuntherng J; Blake RA; Sun L; Tang C; Miller T; Shirazian S; McMahon G; Cherrington JM
    Clin Cancer Res; 2003 Jan; 9(1):327-37. PubMed ID: 12538485
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function.
    Maita S; Yuasa T; Tsuchiya N; Mitobe Y; Narita S; Horikawa Y; Hatake K; Fukui I; Kimura S; Maekawa T; Habuchi T
    Int J Cancer; 2012 Feb; 130(3):677-84. PubMed ID: 21387300
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sunitinib improves chemotherapeutic efficacy and ameliorates cisplatin-induced nephrotoxicity in experimental animals.
    Suddek GM
    Cancer Chemother Pharmacol; 2011 May; 67(5):1035-44. PubMed ID: 20652569
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase.
    Sun L; Liang C; Shirazian S; Zhou Y; Miller T; Cui J; Fukuda JY; Chu JY; Nematalla A; Wang X; Chen H; Sistla A; Luu TC; Tang F; Wei J; Tang C
    J Med Chem; 2003 Mar; 46(7):1116-9. PubMed ID: 12646019
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A tyrosine kinase inhibitor-based high-affinity PET radiopharmaceutical targets vascular endothelial growth factor receptor.
    Li F; Jiang S; Zu Y; Lee DY; Li Z
    J Nucl Med; 2014 Sep; 55(9):1525-31. PubMed ID: 24970912
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics.
    Haubner R; Wester HJ; Burkhart F; Senekowitsch-Schmidtke R; Weber W; Goodman SL; Kessler H; Schwaiger M
    J Nucl Med; 2001 Feb; 42(2):326-36. PubMed ID: 11216533
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular basis for sunitinib efficacy and future clinical development.
    Faivre S; Demetri G; Sargent W; Raymond E
    Nat Rev Drug Discov; 2007 Sep; 6(9):734-45. PubMed ID: 17690708
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
    Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
    Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
    [TBL] [Abstract][Full Text] [Related]  

  • 49. VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells.
    Doi Y; Yashiro M; Yamada N; Amano R; Noda S; Hirakawa K
    Ann Surg Oncol; 2012 Aug; 19(8):2733-43. PubMed ID: 22207048
    [TBL] [Abstract][Full Text] [Related]  

  • 50. SU11248 (sunitinib) directly inhibits the activity of mammalian 5'-AMP-activated protein kinase (AMPK).
    Laderoute KR; Calaoagan JM; Madrid PB; Klon AE; Ehrlich PJ
    Cancer Biol Ther; 2010 Jul; 10(1):68-76. PubMed ID: 20495370
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
    Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
    Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sunitinib inhibits the phosphorylation of platelet-derived growth factor receptor β in the skin of mice with scleroderma-like features and prevents the development of the disease.
    Kavian N; Servettaz A; Marut W; Nicco C; Chéreau C; Weill B; Batteux F
    Arthritis Rheum; 2012 Jun; 64(6):1990-2000. PubMed ID: 22213155
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors.
    Shojaei F; Lee JH; Simmons BH; Wong A; Esparza CO; Plumlee PA; Feng J; Stewart AE; Hu-Lowe DD; Christensen JG
    Cancer Res; 2010 Dec; 70(24):10090-100. PubMed ID: 20952508
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mononuclear gold(III) complexes with phenanthroline ligands as efficient inhibitors of angiogenesis: A comparative study with auranofin and sunitinib.
    Pavic A; Glišić BĐ; Vojnovic S; Warżajtis B; Savić ND; Antić M; Radenković S; Janjić GV; Nikodinovic-Runic J; Rychlewska U; Djuran MI
    J Inorg Biochem; 2017 Sep; 174():156-168. PubMed ID: 28675847
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sunitinib malate.
    Izzedine H; Buhaescu I; Rixe O; Deray G
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):357-64. PubMed ID: 17136543
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sunitinib suppresses tumor growth and metastases in a highly metastatic mouse mammary cancer model.
    Tanaka Y; Shibata MA; Morimoto J; Otsuki Y
    Anticancer Res; 2011 Apr; 31(4):1225-34. PubMed ID: 21508369
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sunitinib: from charge-density studies to interaction with proteins.
    Malińska M; Jarzembska KN; Goral AM; Kutner A; Woźniak K; Dominiak PM
    Acta Crystallogr D Biol Crystallogr; 2014 May; 70(Pt 5):1257-70. PubMed ID: 24816095
    [TBL] [Abstract][Full Text] [Related]  

  • 58. DNA binding of sunitinib: Spectroscopic evidence via circular dichroism and nuclear magnetic resonance.
    Kiss E; Mirzahosseini A; Hubert Á; Ambrus A; Őrfi L; Horváth P
    J Pharm Biomed Anal; 2018 Feb; 150():355-361. PubMed ID: 29287262
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sunitinib malate.
    Kassem MG; Motiur Rahman AF; Korashy HM
    Profiles Drug Subst Excip Relat Methodol; 2012; 37():363-88. PubMed ID: 22469323
    [No Abstract]   [Full Text] [Related]  

  • 60. 5-O-(4-[125 I]Iodobenzyl)-L-ascorbic acid: electrophilic radioiodination and biodistribution in mice.
    Kim J; Kino T; Kato H; Yamamoto F; Sano K; Mukai T; Maeda M
    Chem Pharm Bull (Tokyo); 2012; 60(2):235-40. PubMed ID: 22293483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.